Why the study?
Prior measurement of adrenergic receptor autoantibody activity in POTS relied on costly, low-throughput, and laborious physiological assays, motivating the development of a cell-based bioassay.
Does a novel MAO-pretreated cell-based bioassay detect increased adrenergic autoantibody activity in patients with POTS compared to healthy controls?
Does a novel MAO-pretreated cell-based bioassay detect increased adrenergic autoantibody activity in patients with POTS compared to healthy controls?
A novel cell-based bioassay with MAO pre-treatment demonstrates that POTS patients have significantly increased α1AR and β1AR autoantibody activity compared to healthy controls, supporting an autoimmune contribution to POTS.
New assay enables scalable AAb testing in POTS; leaves open pathogenic role and therapeutic implications.
Background Activating autoantibodies (AAb) to adrenergic receptors (AR) have previously been reported in patients with postural tachycardia syndrome (POTS). These AAb may contribute to a final common pathway for overlapping disease processes, reflecting a possible autoimmune contribution to POTS pathophysiology. In prior studies, measurement of AAb activity was inferred from costly, low-throughput, and laborious physiological assays. In the present study, we developed and validated an alternative cell-based bioassay for measuring AAb activity in serum by means of pre-treatment with monoamine oxidase (MAO). Methods A total of 37 POTS patients and 61 sex-matched healthy control participants were included. Serum was pre-treated with MAO to remove endogenous catecholamines that could falsely inflate AR activation by AAb. A receptor-transfected cell-based bioassay was used to detect presence of α1AR-AAb and β1AR-AAb in serum. Results MAO effectively degraded catecholamines as demonstrated by suppression of norepinephrine-induced α1AR activation in POTS (6.4 ± 0.7 vs. 5.5 ± 0.9; P = 0.044) and in controls (4.1 ± 0.5 vs. 3.9 ± 0.6; P = 0.001). Mean activity values were greater in the POTS vs. Controls for α1AR-AAb (6.2 ± 1.2 vs. 5.3 ± 1.0; P < 0.001) and β1AR-AAb (5.7 ± 1.8 vs. 4.1 ± 0.9; P < 0.001). Compared to controls, more POTS patients were positive for α1AR-AAb activity (22% vs 4%; P = 0.007) and β1AR-AAb activity (52% vs. 2%; P < 0.001). Conclusions The co-presence of norepinephrine in serum samples can artifactually elevate α1AR and β1AR activity, which can be avoided by serum pre-treatment with MAO. Using this novel bioassay, we show that POTS patients have increased α1AR-AAb and β1AR-AAb activity compared to healthy controls in the largest POTS cohort reported to-date.
No takes yet. Share an insight, caveat, or question.
Badiudeen et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: